Janus Henderson Group PLC Boosts Stock Position in Biohaven Ltd. $BHVN

Janus Henderson Group PLC lifted its stake in Biohaven Ltd. (NYSE:BHVN) by 1,145.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,534,612 shares of the company’s stock after purchasing an additional 16,127,247 shares during the quarter. Janus Henderson Group PLC owned about 0.12% of Biohaven worth $148,214,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BHVN. PNC Financial Services Group Inc. boosted its stake in Biohaven by 113.7% during the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after acquiring an additional 1,450 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after acquiring an additional 2,583 shares during the period. Arax Advisory Partners raised its holdings in shares of Biohaven by 943.3% during the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock worth $55,000 after acquiring an additional 4,443 shares during the period. Finally, Leonteq Securities AG acquired a new position in shares of Biohaven during the 4th quarter valued at about $78,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BHVN shares. Canaccord Genuity Group initiated coverage on shares of Biohaven in a research report on Monday, April 13th. They set a “buy” rating and a $21.00 price objective for the company. Bank of America reissued an “underperform” rating and issued a $11.00 price target (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. HC Wainwright reaffirmed a “neutral” rating and set a $10.00 price target on shares of Biohaven in a research report on Tuesday, May 26th. Finally, Morgan Stanley decreased their price objective on Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Biohaven has an average rating of “Moderate Buy” and a consensus price target of $21.62.

Biohaven Stock Down 2.4%

Shares of BHVN opened at $13.49 on Friday. The firm has a market cap of $2.03 billion, a P/E ratio of -2.38 and a beta of 1.28. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The company’s 50-day moving average price is $13.60 and its 200 day moving average price is $11.57. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, sell-side analysts forecast that Biohaven Ltd. will post -3.1 earnings per share for the current year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.